Advertisement
Advertisement
VRDN
Viridian Therapeutics, Inc. Common Stock
20.47
USDSponsored
-0.19
-0.92%
Sep 25, 15:59 UTC -4
Closed
After-Market
20.47
0.00
0.00%
VRDN Earnings Reports
Positive Surprise Ratio
VRDN beat 24 of 41 last estimates.
59%
Next Report
Date of Next Report
Nov 03, 2026
Estimate for Q3 26 (Revenue/ EPS)
$10.30M
/-$0.98
Implied change from Q2 26 (Revenue/ EPS)
+3528.46%
/-6.67%
Implied change from Q3 25 (Revenue/ EPS)
-85.40%
/+188.24%
Viridian Therapeutics, Inc. Common Stock earnings per share and revenue
On Aug 06, 2026, VRDN reported earnings of -1.05 USD per share (EPS) for Q2 26, missing the estimate of -1.04 USD, resulting in a -0.01% surprise. Revenue reached 284.00 thousand, compared to an expected 22.76 thousand, with a 1148.02% difference. The market reacted with a +6.83% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 10 analysts forecast an EPS of -0.98 USD, with revenue projected to reach 10.30 million USD, implying an decrease of -6.67% EPS, and increase of 3528.46% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
FAQ
What were Viridian Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Viridian Therapeutics, Inc. Common Stock reported EPS of -$1.05, missing estimates by -0.01%, and revenue of $284.00K, 1148.02% above expectations.
How did the market react to Viridian Therapeutics, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 6.83%, changed from $21.07 before the earnings release to $22.51 the day after.
When is Viridian Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 03, 2026.
What are the forecasts for Viridian Therapeutics, Inc. Common Stock's next earnings report?
Based on 10
analysts, Viridian Therapeutics, Inc. Common Stock is expected to report EPS of -$0.98 and revenue of $10.30M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.